EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • August 13th, 2018 • Dare Bioscience, Inc. • Pharmaceutical preparations • Massachusetts
This Exclusive License Agreement (hereinafter referred to as this “Agreement”), effective as of September 15, 2017 (the “Effective Date”), is entered into by and between Fred Mermelstein, Ph.D. and Janet Chollet, M.D., (collectively referred to as the “Licensors”), Pear Tree Pharmaceuticals, Inc., a corporation duly organized and existing under the laws of the State of Delaware (the “Licensee”), and Stephen Rocamboli (“Rocamboli”).
EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • August 13th, 2018 • Dare Bioscience, Inc. • Pharmaceutical preparations • Massachusetts
This Exclusive License Agreement (this “Agreement”) is made as April 24, 2018 (“Effective Date”), by and between Juniper Pharmaceuticals, Inc., a Delaware corporation, (“Juniper’’) and Daré Bioscience, Inc., a Delaware corporation (“Licensee”), each referred to herein individually as a “Party” and collectively as the “Parties”.
AGREEMENT AND PLAN OF MERGERAgreement and Plan of Merger • August 13th, 2018 • Dare Bioscience, Inc. • Pharmaceutical preparations • Delaware
THIS AGREEMENT AND PLAN OF MERGER (this “Agreement”) is dated as of April 30, 2018, by and among Daré Bioscience, Inc., a Delaware corporation (“Parent”), Daré Merger Sub, Inc., a Delaware corporation (“Merger Sub”), Pear Tree Pharmaceuticals, Inc., a Delaware corporation (the “Company”) and Fred Mermelstein and Stephen C. Rocamboli, as Holders’ Representatives. Each of Parent, Merger Sub, the Company and Holders’ Representatives may be individually referred to herein as a “Party” and collectively referred to herein as the “Parties.”
Incentive Stock Option Agreement Granted Under the Amended and Restated 2014 Stock Incentive PlanIncentive Stock Option Agreement • August 13th, 2018 • Dare Bioscience, Inc. • Pharmaceutical preparations
AMENDMENT NO. 1 TO THE AMENDED AND RESTATED EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • August 13th, 2018 • Dare Bioscience, Inc. • Pharmaceutical preparations • Massachusetts
This Amendment No. 1 to the Amended and Restated Exclusive License Agreement (hereinafter referred to as this “Agreement”) is entered into by and among Fred Mermelstein, Ph.D. and Janet Chollet, MD (the “Licensor”) and Pear Tree Pharmaceuticals, Inc., a corporation duly organized and existing under the laws of the State of Delaware (the “Licensee”), on this October 10, 2007.
EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • August 13th, 2018 • Dare Bioscience, Inc. • Pharmaceutical preparations • Massachusetts
THIS EXCLUSIVE LICENSE AGREEMENT (this “Agreement”) dated as of Feb. 13, 2017 (the “Effective Date”) is entered into between GYN Holdings, Inc. a Delaware corporation having a place of business at c/o Pear Tree Pharmaceuticals, Suite 4-200, 275 Grove Street, Newton, MA 02466 (“Company”) and Bernadette Klamerus, an individual with a mailing address at P.O. Box 225 Carmichaels, PA 15320 (the “Licensor”).
Nonstatutory Stock Option Agreement Granted Under the Amended and Restated 2014 Stock Incentive PlanNonstatutory Stock Option Agreement • August 13th, 2018 • Dare Bioscience, Inc. • Pharmaceutical preparations
AMENDMENT NO. 2 TO THE AMENDED AND RESTATED EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • August 13th, 2018 • Dare Bioscience, Inc. • Pharmaceutical preparations • Massachusetts
This Amendment No. 2 to the Amended and Restated Exclusive License Agreement (hereinafter referred to as this “Agreement”) is entered into by and among Fred Mermelstein, Ph.D. and Janet Chollet, M.D. (the “Licensors”), Pear Tree Pharmaceuticals, Inc., a corporation duly organized and existing under the laws of the State of Delaware (the “Licensee”) and Bernadette Klamerus (“Klamerus”), on this February 13, 2017.
